

Massimo Breccia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7737933/publications.pdf>

Version: 2024-02-01

718
papers

14,060
citations

31902

53
h-index

40881

93
g-index

727
all docs

727
docs citations

727
times ranked

11287
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
2	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013, 121, 4439-4442.	0.6	546
3	European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. <i>Leukemia</i> , 2016, 30, 1648-1671.	3.3	369
4	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	0.8	299
5	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
6	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. <i>New England Journal of Medicine</i> , 2019, 381, 2315-2326.	13.9	257
7	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1995-1999.	0.6	225
8	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011, 118, 4554-4560.	0.6	221
9	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. <i>Blood</i> , 2009, 114, 4933-4938.	0.6	203
10	Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. <i>Leukemia</i> , 2002, 16, 2185-2189.	3.3	176
11	Therapy-related myelodysplastic syndrome—acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002, 99, 822-824.	0.6	125
12	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677.	0.8	121
13	Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2013, 27, 1511-1519.	3.3	119
14	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007, 21, 79-83.	3.3	108
15	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
16	Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. <i>Leukemia Research</i> , 2004, 28, 1165-1169.	0.4	100
17	Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. <i>British Journal of Cancer</i> , 2012, 107, 904-909.	2.9	100
18	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97

#	ARTICLE	IF	CITATIONS
19	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
20	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008, 93, 1792-1796.	1.7	91
21	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	3.2	90
22	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84
23	Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002, 116, 576-581.	1.2	80
24	Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 1566-8.	1.7	78
25	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	3.3	77
26	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	0.8	76
27	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
28	PML-RAR α kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. <i>Leukemia</i> , 2016, 30, 1987-1992.	3.3	75
29	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003, 102, 1035-1041.	0.6	74
30	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009, 94, 205-212.	1.7	73
31	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
32	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71
33	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015, 29, 1084-1091.	3.3	70
34	International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. <i>Quality of Life Research</i> , 2014, 23, 825-836.	1.5	67
35	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
36	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011, 96, 696-702.	1.7	64

#	ARTICLE	IF	CITATIONS
37	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012, 119, 49-54.	0.6	63
38	Expert opinion on management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. <i>Leukemia</i> , 2020, 34, 1495-1502.	3.3	63
39	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
40	Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005, 74, 121-123.	1.1	62
41	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	3.3	62
42	Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. <i>Annals of Hematology</i> , 2015, 94, 393-397.	0.8	62
43	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
44	Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012, 97, 560-567.	1.7	61
45	Current standard treatment of adult acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 841-854.	1.2	60
46	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	0.6	59
47	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	0.8	59
48	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	1.2	59
49	A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with $\geq 30\%$ blasts. <i>Leukemia</i> , 2017, 31, 2799-2806.	3.3	59
50	Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007, 31, 1770-1772.	0.4	58
51	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	1.7	58
52	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
53	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.4	57
54	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57

#	ARTICLE	IF	CITATIONS
55	Ponatinib: A Review of Efficacy and Safety. <i>Current Cancer Drug Targets</i> , 2018, 18, 847-856.	0.8	57
56	Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 129-134.	0.4	56
57	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	2.0	56
58	Hypermethylation of CpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. <i>Leukemia</i> , 2003, 17, 919-924.	3.3	55
59	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	1.2	54
60	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	0.6	54
61	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- γ : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774.	1.7	53
62	Real-life results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 1472-1475.	0.4	53
63	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	0.8	53
64	Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?. <i>Annals of Hematology</i> , 2012, 91, 1371-1381.	0.8	51
65	Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. <i>Leukemia and Lymphoma</i> , 2009, 50, 387-391.	0.6	50
66	Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1273-1274.	1.7	49
67	Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. <i>Leukemia Research</i> , 2008, 32, 1626-1628.	0.4	49
68	Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. <i>Haematologica</i> , 2010, 95, 853-854.	1.7	49
69	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	6.9	49
70	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49
71	FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013, 98, e161-e163.	1.7	49
72	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	0.8	48

#	ARTICLE	IF	CITATIONS
73	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017, 96, 549-558.	0.8	48
74	Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. <i>British Journal of Haematology</i> , 2003, 120, 266-270.	1.2	47
75	NF- κ B as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1157-1176.	1.5	46
76	Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1031-1043.	0.9	46
77	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
78	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
79	Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008, 32, 1022-1025.	0.4	45
80	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	6.9	45
81	Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005, 74, 89-90.	1.1	44
82	The response to imatinib and interferon- α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010, 95, 1415-1419.	1.7	43
83	How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review. <i>Leukemia Research</i> , 2014, 38, 1392-1398.	0.4	43
84	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	1.7	42
85	Thrombo-hemorrhagic deaths in acute promyelocytic leukemia. <i>Thrombosis Research</i> , 2014, 133, S112-S116.	0.8	41
86	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
87	Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Cancer</i> , 2012, 118, 404-409.	2.0	40
88	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015, 23, 3289-3295.	1.0	39
89	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	1.7	39
90	Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003, 17, 925-930.	3.3	38

#	ARTICLE	IF	CITATIONS
91	Comorbidities and FLT3–ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. Hematological Oncology, 2009, 27, 148-153.	0.8	38
92	Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes. Annals of Oncology, 2014, 25, 447-454.	0.6	38
93	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leukemia Research, 2010, 34, 143-147.	0.4	37
94	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher–risk myelodysplastic syndromes or chronic myelomonocytic leukemia. European Journal of Haematology, 2013, 90, 345-348.	1.1	37
95	Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Blood, 2020, 136, 47-50.	0.6	37
96	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leukemia and Lymphoma, 2010, 51, 1007-1014.	0.6	36
97	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leukemia Research, 2011, 35, 159-162.	0.4	36
98	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. Drugs and Aging, 2013, 30, 629-637.	1.3	36
99	Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?. Cancer Letters, 2011, 300, 115-121.	3.2	35
100	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	3.3	35
101	Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opinion on Biological Therapy, 2011, 11, 225-234.	1.4	34
102	Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leukemia Research, 2008, 32, 514-516.	0.4	33
103	Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leukemia Research, 2013, 37, 713-720.	0.4	33
104	Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. American Journal of Hematology, 2014, 89, 542-546.	2.0	33
105	Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated “sanctuary“?. Leukemia, 2002, 16, 1127-1130.	3.3	32
106	Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leukemia Research, 2014, 38, 294-298.	0.4	32
107	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Annals of Hematology, 2018, 97, 1577-1580.	0.8	32
108	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	0.8	32

#	ARTICLE	IF	CITATIONS
109	Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. <i>Haematologica</i> , 2020, 105, 1559-1566.	1.7	32
110	How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). <i>Cancer Medicine</i> , 2020, 9, 4160-4165.	1.3	32
111	Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. <i>Leukemia</i> , 2006, 20, 1978-1988.	3.3	31
112	Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. <i>Leukemia Research</i> , 2006, 30, 1577-1579.	0.4	31
113	Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012, 91, 1345-1349.	0.8	31
114	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	1.1	31
115	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	2.0	31
116	Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. <i>Haematologica</i> , 2004, 89, 29-33.	1.7	31
117	Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. <i>Annals of Oncology</i> , 2006, 17, 281-285.	0.6	30
118	Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies. <i>Haematologica</i> , 2007, 92, 666-673.	1.7	30
119	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
120	Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 1293-1301.	3.3	29
121	Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 93-100.	2.0	29
122	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	0.6	29
123	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347.	2.8	29
124	Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
125	Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. <i>Cancer</i> , 2006, 107, 1008-1013.	2.0	28
126	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. <i>Clinical Cancer Research</i> , 2009, 15, 1059-1063.	3.2	28

#	ARTICLE	IF	CITATIONS
127	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28
128	Efficacy and safety of deferasirox in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2013, 92, 863-870.	0.8	28
129	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016, 91, 318-321.	2.0	28
130	A journey through infectious risk associated with ruxolitinib. <i>British Journal of Haematology</i> , 2019, 187, 286-295.	1.2	28
131	Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071982644.	1.1	28
132	The importance of molecular monitoring in acute promyelocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 503-520.	0.7	27
133	Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. <i>Leukemia Research</i> , 2008, 32, 519-520.	0.4	27
134	Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 123-135.	2.0	26
135	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	2.0	26
136	The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. <i>Annals of Oncology</i> , 1997, 8, 1273-1275.	0.6	25
137	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low- and Intermediate-1 risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	1.1	25
138	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015, 94, 771-777.	0.8	25
139	Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation. <i>European Journal of Haematology</i> , 2003, 70, 190-192.	1.1	24
140	Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. <i>Leukemia Research</i> , 2008, 32, 835-836.	0.4	24
141	Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. <i>Leukemia Research</i> , 2012, 36, e66-e67.	0.4	24
142	Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). <i>BioDrugs</i> , 2014, 28, 17-26.	2.2	24
143	Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?. <i>Annals of Hematology</i> , 2014, 93, 1951-1952.	0.8	24
144	Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24

#	ARTICLE	IF	CITATIONS
145	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
146	Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge. <i>Journal of Clinical Medicine</i> , 2021, 10, 515.	1.0	24
147	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
148	Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004, 89, 866-8.	1.7	24
149	Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. <i>British Journal of Haematology</i> , 2002, 116, 299-307.	1.2	23
150	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005, 29, 749-754.	0.4	23
151	Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 713-721.	1.0	23
152	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	0.8	23
153	Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014, 93, 1819-1823.	0.8	23
154	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197.	0.4	23
155	Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. <i>British Journal of Haematology</i> , 2017, 177, 741-750.	1.2	23
156	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
157	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. <i>Bone Marrow Transplantation</i> , 2020, 55, 708-716.	1.3	23
158	Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?. <i>British Journal of Haematology</i> , 2002, 118, 438-441.	1.2	22
159	The metabolic consequences of imatinib mesylate: Changes on glucose, lipidic and bone metabolism. <i>Leukemia Research</i> , 2009, 33, 871-875.	0.4	22
160	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	1.2	22
161	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. <i>Haematologica</i> , 2012, 97, 1731-1735.	1.7	22
162	SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014003.	0.5	22

#	ARTICLE	IF	CITATIONS
163	Deferasirox chelation therapy in patients with transfusion-dependent <scp>MDS</scp>: a "real-world"™ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015, 95, 52-56.	1.1	22
164	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	1.7	22
165	Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	2.0	22
166	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999, 106, 133-141.	1.2	21
167	Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007, 86, 263-270.	0.8	21
168	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	0.8	21
169	Therapeutic strategies in low and high-risk MDS: What does the future have to offer?. <i>Blood Reviews</i> , 2021, 45, 100689.	2.8	21
170	Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005, 29, 287-291.	0.4	20
171	Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response. <i>Acta Haematologica</i> , 2010, 124, 46-48.	0.7	20
172	Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011, 96, 1390-1391.	1.7	20
173	LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011021.	0.5	20
174	Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. <i>Leukemia and Lymphoma</i> , 2012, 53, 985-986.	0.6	20
175	MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. <i>Haematologica</i> , 2012, 97, e2-e2.	1.7	20
176	FLT3-ITD in acute promyelocytic leukemia: Clinical distinct profile but still controversial prognosis. <i>Leukemia Research</i> , 2015, 39, 397-399.	0.4	20
177	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	0.8	20
178	Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. <i>Blood</i> , 2016, 128, 625-625.	0.6	20
179	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
180	Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. <i>Leukemia</i> , 2004, 18, 361-362.	3.3	19

#	ARTICLE	IF	CITATIONS
181	The EUTOS score identifies chronic myeloid leukemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012, 36, e209-e210.	0.4	19
182	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013, 333, 32-35.	3.2	19
183	Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome “Emphasis on optimized dosing schedules and new formulations. <i>Leukemia Research</i> , 2015, 39, 1028-1033.	0.4	19
184	Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016, 96, 643-649.	1.1	19
185	Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018, 20, 23.	1.8	19
186	Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option. <i>Clinical Drug Investigation</i> , 2018, 38, 475-476.	1.1	19
187	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	0.8	19
188	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
189	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	0.6	19
190	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	0.8	19
191	Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2008, 120, 104-107.	0.7	18
192	Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. <i>Supportive Care in Cancer</i> , 2016, 24, 4887-4894.	1.0	18
193	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	0.8	18
194	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808.	0.8	18
195	Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 883.	1.3	18
196	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSC. <i>Blood</i> , 2012, 120, 6-6.	0.6	18
197	A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	18
198	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999, 13, 514-517.	3.3	17

#	ARTICLE	IF	CITATIONS
199	Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004, 18, 182-182.	3.3	17
200	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006, 30, 178-182.	0.4	17
201	Late Relapses in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2007, 117, 106-108.	0.7	17
202	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008, 93, 1918-1920.	1.7	17
203	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 783-788.	0.6	17
204	Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 expression at baseline. <i>British Journal of Haematology</i> , 2015, 169, 148-150.	1.2	17
205	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 859-865.	0.4	17
206	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
207	Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019, 37, 652-654.	0.8	17
208	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. <i>British Journal of Haematology</i> , 2021, 193, 129-132.	1.2	17
209	Granulocytic Sarcoma with Breast and Skin Presentation: A Report of a Case Successfully Treated by Local Radiation and Systemic Chemotherapy. <i>Acta Haematologica</i> , 2000, 104, 34-37.	0.7	16
210	Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. <i>Annals of Hematology</i> , 2001, 80, 614-616.	0.8	16
211	Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. <i>British Journal of Haematology</i> , 2001, 113, 136-142.	1.2	16
212	5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. <i>Leukemia and Lymphoma</i> , 2012, 53, 1558-1560.	0.6	16
213	Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: Treatment-free remission as a new goal in chronic myeloid leukemia. <i>Cancer Letters</i> , 2014, 347, 22-28.	3.2	16
214	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808.	3.3	16
215	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
216	Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1-9.	1.9	16

#	ARTICLE	IF	CITATIONS
217	Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. <i>Leukemia Research</i> , 2008, 32, 177-180.	0.4	15
218	Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients. <i>BioDrugs</i> , 2011, 25, 147-157.	2.2	15
219	The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 135-143.	2.0	15
220	Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine. <i>Annals of Hematology</i> , 2013, 92, 411-412.	0.8	15
221	Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015, 94, 195-200.	0.8	15
222	Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 190-198.	2.0	15
223	Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 376-388.	2.0	15
224	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
225	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774.	0.8	15
226	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	3.3	15
227	Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. <i>American Journal of Hematology</i> , 2020, 95, E260-E263.	2.0	15
228	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
229	Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen. <i>European Journal of Haematology</i> , 2002, 68, 1-3.	1.1	14
230	Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 2328-2332.	0.6	14
231	Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009, 33, e134-e136.	0.4	14
232	How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages. <i>Cancer Letters</i> , 2012, 322, 127-132.	3.2	14
233	Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR ¹² rearrangement and type 1 diabetes. <i>Annals of Hematology</i> , 2012, 91, 1823-1824.	0.8	14
234	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14

#	ARTICLE	IF	CITATIONS
235	Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. <i>American Journal of Hematology</i> , 2015, 90, E100-1.	2.0	14
236	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, E661-E664.	2.0	14
237	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017, 96, 387-391.	0.8	14
238	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	0.8	14
239	A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with P^h-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2020, 95, E329-E332.	2.0	14
240	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	3.3	14
241	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
242	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
243	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	0.6	14
244	The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. <i>Blood</i> , 2012, 120, 1678-1678.	0.6	14
245	Conservative treatment for patients over 80 years with acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2002, 71, 256-259.	2.0	13
246	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.4	13
247	Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 21-28.	0.2	13
248	Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. <i>American Journal of Hematology</i> , 2010, 85, 960-963.	2.0	13
249	Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. <i>Haematologica</i> , 2011, 96, e41-e42.	1.7	13
250	Evaluation of residual CD34 ⁺ Ph ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269.	2.0	13
251	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. <i>Leukemia and Lymphoma</i> , 2016, 57, 99-102.	0.6	13
252	Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a real-life patient population with chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2017, 35, 232-236.	0.8	13

#	ARTICLE	IF	CITATIONS
253	Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1001-1008.	1.5	13
254	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. <i>Annals of Hematology</i> , 2020, 99, 65-72.	0.8	13
255	Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2004, 89, 615-7.	1.7	13
256	Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. <i>Hematological Oncology</i> , 2010, 28, 89-92.	0.8	12
257	The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). <i>Haematologica</i> , 2011, 96, e23-e24.	1.7	12
258	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. <i>Leukemia Research</i> , 2011, 35, 504-507.	0.4	12
259	Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>Leukemia Research</i> , 2012, 36, 804-805.	0.4	12
260	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183.	0.8	12
261	Systematic review of dasatinib in chronic myeloid leukemia. <i>OncoTargets and Therapy</i> , 2013, 6, 257.	1.0	12
262	Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd. <i>Blood</i> , 2012, 120, 1686-1686.	0.6	12
263	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. <i>Leukemia Research</i> , 2005, 29, 33-39.	0.4	11
264	Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. <i>European Journal of Haematology</i> , 2005, 75, 396-400.	1.1	11
265	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 314-317.	0.4	11
266	Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. <i>Leukemia Research</i> , 2016, 48, 20-25.	0.4	11
267	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754.	0.8	11
268	Comparison of <i>JAK2</i> ^{V617F} -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275.	0.8	11
269	Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 81-87.	1.0	11
270	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416.	0.8	11

#	ARTICLE	IF	CITATIONS
271	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Frontiers in Oncology</i> , 2021, 11, 642005.	1.3	11
272	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	2.4	11
273	Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). <i>Annals of Hematology</i> , 2021, 100, 481-485.	0.8	11
274	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11
275	Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020062.	0.5	11
276	Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy. <i>Acta Haematologica</i> , 2007, 118, 162-164.	0.7	10
277	Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: Further evidence for the arbitrary nature of current classification systems. <i>Leukemia and Lymphoma</i> , 2008, 49, 1292-1296.	0.6	10
278	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. <i>American Journal of Hematology</i> , 2010, 85, 375-377.	2.0	10
279	EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014011.	0.5	10
280	Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. <i>American Journal of Hematology</i> , 2015, 90, 105-108.	2.0	10
281	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	2.0	10
282	Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 525-533.	1.0	10
283	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 623-628.	1.0	10
284	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019, 98, 1891-1904.	0.8	10
285	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	0.8	10
286	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
287	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
288	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103163.	2.0	10

#	ARTICLE	IF	CITATIONS
289	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 1979-1979.	0.6	10
290	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2016, 128, 3070-3070.	0.6	10
291	Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. Blood, 2014, 124, 3141-3141.	0.6	10
292	Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. British Journal of Haematology, 2002, 116, 299-307.	1.2	10
293	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Frontiers in Oncology, 2022, 12, 839915.	1.3	10
294	Acute Myeloid Leukemia Secondary to a Myelodysplastic Syndrome with t(3;3) (q21;q26) in an HIV Patient Treated with Chemotherapy and Highly Active Antiretroviral Therapy. Acta Haematologica, 2004, 111, 160-162.	0.7	9
295	Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis. European Journal of Haematology, 2004, 73, 304-306.	1.1	9
296	Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?. European Journal of Haematology, 2005, 75, 89-90.	1.1	9
297	Role of β -glutamyl cysteine synthetase (β -GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias. Clinica Chimica Acta, 2006, 365, 342-345.	0.5	9
298	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. Leukemia and Lymphoma, 2009, 50, 114-118.	0.6	9
299	Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a "grey zone" at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. British Journal of Haematology, 2011, 152, 119-121.	1.2	9
300	Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who's afraid of the big bad wolf?. Leukemia Research, 2012, 36, 813-814.	0.4	9
301	Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Supportive Care in Cancer, 2016, 24, 4487-4493.	1.0	9
302	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Medicine, 2017, 6, 1233-1239.	1.3	9
303	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	0.8	9
304	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian "Back to Life" project. Quality of Life Research, 2018, 27, 1545-1554.	1.5	9
305	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	0.8	9
306	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	0.8	9

#	ARTICLE	IF	CITATIONS
307	RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort. <i>Blood Advances</i> , 2022, 6, 4424-4426.	2.5	9
308	Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2008, 32, 353-355.	0.4	8
309	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 994-997.	0.6	8
310	Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?. <i>Bone Marrow Transplantation</i> , 2009, 44, 331-332.	1.3	8
311	Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma. <i>Leukemia Research</i> , 2010, 34, e300-e301.	0.4	8
312	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	0.6	8
313	Second line small molecule therapy options for treating chronic myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 57-65.	0.9	8
314	How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes. <i>Expert Review of Hematology</i> , 2017, 10, 155-159.	1.0	8
315	Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. <i>Expert Review of Hematology</i> , 2018, 11, 301-306.	1.0	8
316	Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. <i>British Journal of Haematology</i> , 2018, 181, 267-270.	1.2	8
317	Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. <i>British Journal of Haematology</i> , 2018, 182, 427-429.	1.2	8
318	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019, 98, 1919-1925.	0.8	8
319	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. <i>Leukemia Research</i> , 2019, 76, 65-69.	0.4	8
320	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020, 61, 536-545.	0.6	8
321	The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020, 13, 1067-1072.	1.0	8
322	Direct oral anticoagulants in patients with hematologic malignancies. <i>Hematological Oncology</i> , 2020, 38, 589-596.	0.8	8
323	Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1199-1209.	0.5	8
324	Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2021, 24, 887-893.	0.6	8

#	ARTICLE	IF	CITATIONS
325	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	0.8	8
326	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. <i>Cancers</i> , 2021, 13, 4750.	1.7	8
327	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the Ph1-negative Myeloproliferative Neoplasms Latium Group. <i>European Journal of Haematology</i> , 2020, 105, 335-343.	1.1	8
328	Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. <i>Blood</i> , 2018, 132, 792-792.	0.6	8
329	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 44-44.	0.6	8
330	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. <i>Blood</i> , 2009, 114, 2205-2205.	0.6	8
331	AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. <i>Haematologica</i> , 2002, 87, ELT12.	1.7	8
332	Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3597.	1.0	8
333	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005, 36, 83-84.	1.3	7
334	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011, 86, 523-525.	2.0	7
335	Management of the 2009 A/H1N1 Influenza Pandemic in Patients with Hematologic Diseases: A Prospective Experience at an Italian Center. <i>Acta Haematologica</i> , 2011, 126, 1-7.	0.7	7
336	The role of comorbidities in chronic myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 729-730.	0.4	7
337	ATRA + ATO. <i>Current Opinion in Hematology</i> , 2014, 21, 95-101.	1.2	7
338	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420.	0.8	7
339	Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?. <i>Expert Review of Hematology</i> , 2015, 8, 387-389.	1.0	7
340	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a Gruppo Romano Mielodisplasie (GROM) multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065.	0.8	7
341	Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. <i>British Journal of Haematology</i> , 2016, 174, 160-162.	1.2	7
342	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268.	1.7	7

#	ARTICLE	IF	CITATIONS
343	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. American Journal of Hematology, 2017, 92, E668-E670.	2.0	7
344	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	1.2	7
345	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019025.	0.5	7
346	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. Blood, 2019, 134, 1649-1649.	0.6	7
347	Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL. Blood, 2010, 116, 15-15.	0.6	7
348	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood, 2011, 118, 2756-2756.	0.6	7
349	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX&OIL study. British Journal of Haematology, 2022, 197, 190-200.	1.2	7
350	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic&Ophase myelofibrosis. Cancer, 2022, 128, 2449-2454.	2.0	7
351	Pregnancy in patients with myelodysplastic syndromes (MDS). Leukemia Research, 2008, 32, 1605-1607.	0.4	6
352	Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient. International Journal of Hematology, 2009, 89, 720-721.	0.7	6
353	Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. Cancer Chemotherapy and Pharmacology, 2009, 64, 195-197.	1.1	6
354	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. Leukemia Research, 2009, 33, 391-394.	0.4	6
355	Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. Current Drug Targets, 2009, 10, 530-536.	1.0	6
356	5&O2-Azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Leukemia, 2011, 25, 736-737.	3.3	6
357	Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. Leukemia Research, 2011, 35, e215-e216.	0.4	6
358	A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia. Annals of Hematology, 2011, 90, 845-846.	0.8	6
359	Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. Leukemia Research, 2011, 35, e91-e92.	0.4	6
360	The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. Expert Opinion on Pharmacotherapy, 2011, 12, 2075-2087.	0.9	6

#	ARTICLE	IF	CITATIONS
361	Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e402-e403.	0.8	6
362	Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 0-0.	1.2	6
363	Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 2439-2443.	0.6	6
364	Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 497-498.	0.6	6
365	Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far?. <i>Leukemia Research</i> , 2013, 37, 204-205.	0.4	6
366	MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013045.	0.5	6
367	Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014, 167, 428-430.	1.2	6
368	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207.	0.6	6
369	Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. <i>Rare Cancers and Therapy</i> , 2015, 3, 119-132.	0.2	6
370	Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2016, 173, 945-946.	1.2	6
371	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
372	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
373	Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020, 13, 1311-1318.	1.0	6
374	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
375	Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13356.	1.7	6
376	New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2280-2283.	0.6	6
377	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
378	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018, 132, 1750-1750.	0.6	6

#	ARTICLE	IF	CITATIONS
379	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
380	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. <i>Blood</i> , 2015, 126, 2799-2799.	0.6	6
381	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021, 138, 3603-3603.	0.6	6
382	Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. <i>Haematologica</i> , 2004, 89, ECR11.	1.7	6
383	Treatment-free remission in chronic myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 686-696.	0.3	6
384	Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. <i>Haematologica</i> , 2022, 107, 2356-2364.	1.7	6
385	WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?. <i>Leukemia Research</i> , 2009, 33, e93-e94.	0.4	5
386	Nilotinib and dasatinibâ€”new 'magic bullets' for CML?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 557-558.	12.5	5
387	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	0.7	5
388	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11â€“12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189.	2.0	5
389	Current first- and second-line treatment options in acute promyelocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2016, 5, 105-118.	0.7	5
390	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809.	0.8	5
391	Combination of Asciminib+Nilotinib or Asciminib+Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S290-S291.	0.2	5
392	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
393	Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached. <i>EClinicalMedicine</i> , 2020, 19, 100277.	3.2	5
394	Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Expert Review of Hematology</i> , 2021, 14, 293-302.	1.0	5
395	Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 631570.	1.3	5
396	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	2.5	5

#	ARTICLE	IF	CITATIONS
397	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2012, 120, 1680-1680.	0.6	5
398	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. <i>Blood</i> , 2012, 120, 3784-3784.	0.6	5
399	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014, 124, 12-12.	0.6	5
400	Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Imatinib: Introducing the Concept of Confirmed Molecular Response.. <i>Blood</i> , 2007, 110, 1933-1933.	0.6	5
401	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011, 118, 786-786.	0.6	5
402	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	0.6	5
403	Physicians’s Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	1.3	5
404	Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 653-670.	0.7	4
405	Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. <i>Leukemia and Lymphoma</i> , 2009, 50, 848-850.	0.6	4
406	Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment. <i>Leukemia Research</i> , 2010, 34, e122-e124.	0.4	4
407	Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. <i>Leukemia Research</i> , 2010, 34, e224-e225.	0.4	4
408	Clofarabine-Based Regimen as Useful Bridge Therapy for Allogeneic Transplantation in Myeloid Blast Crisis of Philadelphia-Positive Chronic Myeloid Leukemia Resistant to Imatinib and Dasatinib. <i>Acta Haematologica</i> , 2010, 124, 150-152.	0.7	4
409	Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012, 91, 309-310.	0.8	4
410	Imatinib induces body mass changes in women with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 1581-1582.	0.8	4
411	Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization. <i>Leukemia and Lymphoma</i> , 2013, 54, 411-412.	0.6	4
412	Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach. <i>Expert Review of Hematology</i> , 2015, 8, 5-7.	1.0	4
413	Bosutinib for Chronic Myeloid Leukemia. <i>Rare Cancers and Therapy</i> , 2015, 3, 35-46.	0.2	4
414	Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S287-S288.	0.2	4

#	ARTICLE	IF	CITATIONS
415	On the road to treatment-free remission in chronic myeloid leukemia: what about “the others”™?. Expert Review of Anticancer Therapy, 2020, 20, 1075-1081.	1.1	4
416	Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. Annals of Hematology, 2021, 100, 2117-2119.	0.8	4
417	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. Leukemia and Lymphoma, 2021, 62, 1026-1027.	0.6	4
418	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Annals of Hematology, 2021, 100, 1213-1219.	0.8	4
419	The GIMEMA-ALLIANCE Digital Health Platform for Patients With Hematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. JMIR Research Protocols, 2021, 10, e25271.	0.5	4
420	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. Blood, 2018, 132, 45-45.	0.6	4
421	International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). Blood, 2011, 118, 3132-3132.	0.6	4
422	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. Blood, 2016, 128, 1128-1128.	0.6	4
423	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	0.6	4
424	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. Blood, 2015, 126, 2811-2811.	0.6	4
425	Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome. Blood Transfusion, 2014, 12 Suppl 1, s162-3.	0.3	4
426	Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients. Expert Review of Hematology, 2022, 15, 25-32.	1.0	4
427	Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges. International Journal of Hematology, 2022, 116, 586-593.	0.7	4
428	Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival. Acta Haematologica, 2007, 117, 221-225.	0.7	3
429	Isolated molecular relapse in FIP1L1-PDGFR β hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. Cancer Chemotherapy and Pharmacology, 2009, 63, 1161-1163.	1.1	3
430	Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. British Journal of Haematology, 2010, 150, 240-242.	1.2	3
431	Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Leukemia and Lymphoma, 2011, 52, 1372-1375.	0.6	3
432	5- β -Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leukemia Research, 2011, 35, 1409-1411.	0.4	3

#	ARTICLE	IF	CITATIONS
433	Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients. <i>Current Cancer Drug Targets</i> , 2012, 12, 391-401.	0.8	3
434	Can we safely discontinue imatinib? Searching for new endpoints in CML: A standardized definition of "secure". <i>Leukemia Research</i> , 2012, 36, 1498-1499.	0.4	3
435	Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2012, 36, 546-547.	0.4	3
436	Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly. <i>Drugs and Aging</i> , 2013, 30, 467-477.	1.3	3
437	Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. <i>Annals of Hematology</i> , 2013, 92, 1413-1414.	0.8	3
438	Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013, 37, 383-385.	0.4	3
439	Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1621-1630.	0.9	3
440	Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015, 33, 48-51.	0.8	3
441	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	0.5	3
442	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018, 181, 275-278.	1.2	3
443	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584.	1.1	3
444	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. <i>American Journal of Hematology</i> , 2019, 94, E239-E242.	2.0	3
445	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
446	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. <i>Leukemia and Lymphoma</i> , 2021, 62, 739-742.	0.6	3
447	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. <i>Leukemia</i> , 2021, 35, 1814-1816.	3.3	3
448	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROME1). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198.	0.6	3
449	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. <i>Blood</i> , 2018, 132, 458-458.	0.6	3
450	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019, 134, 1652-1652.	0.6	3

#	ARTICLE	IF	CITATIONS
451	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. <i>Blood</i> , 2019, 134, 4145-4145.	0.6	3
452	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009, 114, 2192-2192.	0.6	3
453	Chronic Myeloid Leukemia (CML) Patients with "Suboptimal" Response to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to "Optimal" Responders: A GIMEMA CML WORKING PARTY Analysis.. <i>Blood</i> , 2009, 114, 2196-2196.	0.6	3
454	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009, 114, 860-860.	0.6	3
455	Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016, 128, 1951-1951.	0.6	3
456	Health Related Quality of Life of Long-Term Survivors of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Chemotherapy. <i>Blood</i> , 2016, 128, 2415-2415.	0.6	3
457	Obesity As a Risk Factor for Acute Promyelocytic Leukemia. Results from Population and Case-Control Studies Across Western Countries and Correlation with Gene Expression in the TCGA. <i>Blood</i> , 2016, 128, 448-448.	0.6	3
458	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769.	0.8	3
459	Cocaine abuse may influence the response to imatinib in CML patients. <i>Haematologica</i> , 2007, 92, e41-e42.	1.7	3
460	Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2006, 108, 4776-4776.	0.6	3
461	Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2021, 138, 1283-1283.	0.6	3
462	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022, 30, 4303-4314.	1.0	3
463	Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction. <i>Leukemia and Lymphoma</i> , 2000, 36, 539-541.	0.6	2
464	Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. <i>Leukemia</i> , 2005, 19, 287-289.	3.3	2
465	Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: A possible manifestation of retinoic acid syndrome. <i>Leukemia and Lymphoma</i> , 2007, 48, 833-834.	0.6	2
466	Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. <i>Annals of Hematology</i> , 2007, 86, 295-297.	0.8	2
467	Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib. <i>OncoTargets and Therapy</i> , 2008, 1, 49.	1.0	2
468	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009, 90, 486-491.	0.7	2

#	ARTICLE	IF	CITATIONS
469	Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature. <i>Leukemia Research</i> , 2009, 33, 200-201.	0.4	2
470	Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. <i>Leukemia Research</i> , 2009, 33, 645-648.	0.4	2
471	Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011, 35, e69-e70.	0.4	2
472	Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 707-717.	0.0	2
473	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	2.0	2
474	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2.	2.0	2
475	Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?. <i>Current Medical Research and Opinion</i> , 2016, 32, 1453-1454.	0.9	2
476	Are chronic myeloid leukemia patients ready to stop long-term treatment?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2976-2978.	0.6	2
477	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23.	0.4	2
478	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
479	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019, 42, 660-664.	0.8	2
480	Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019, 81, 25-26.	0.4	2
481	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	1.0	2
482	Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Clinical Drug Investigation</i> , 2020, 40, 1177-1181.	1.1	2
483	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3476-3483.	0.6	2
484	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291.	1.1	2
485	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777.	0.8	2
486	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2

#	ARTICLE	IF	CITATIONS
487	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025.	0.6	2
488	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
489	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
490	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
491	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.	0.6	2
492	In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.. <i>Blood</i> , 2007, 110, 1934-1934.	0.6	2
493	Successful Pregnancy In APL Patients Treated According to the AIDA Protocol.. <i>Blood</i> , 2010, 116, 1037-1037.	0.6	2
494	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010, 116, 2293-2293.	0.6	2
495	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. <i>Blood</i> , 2010, 116, 3413-3413.	0.6	2
496	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,. <i>Blood</i> , 2011, 118, 3783-3783.	0.6	2
497	Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE). <i>Blood</i> , 2013, 122, 1406-1406.	0.6	2
498	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258.	0.6	2
499	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	0.6	2
500	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015, 126, 1606-1606.	0.6	2
501	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. <i>Blood</i> , 2015, 126, 2792-2792.	0.6	2
502	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	0.6	2
503	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942.	0.6	2
504	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. <i>Blood</i> , 2010, 116, 3409-3409.	0.6	2

#	ARTICLE	IF	CITATIONS
505	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	0.6	2
506	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. Blood, 2012, 120, 2797-2797.	0.6	2
507	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4174-4174.	0.6	2
508	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Annals of Hematology, 2022, 101, 1275-1282.	0.8	2
509	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	0.9	2
510	Atypical Chronic Myeloid Leukaemia with CD117-Positive Blast Cells Treated with Imatinib: A Report of Two Cases. Acta Haematologica, 2006, 116, 211-212.	0.7	1
511	Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?. Leukemia Research, 2009, 33, 1450-1451.	0.4	1
512	Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by Frenchâ€“Americanâ€“British and World Health Organisation classifications. Leukemia and Lymphoma, 2009, 50, 841-843.	0.6	1
513	From FAB to 2008 WHO classification: The wide heterogeneity of refractory anemia subtype among different countries. Leukemia Research, 2010, 34, 967-968.	0.4	1
514	Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. Acta OncolÃ³gica, 2010, 49, 399-400.	0.8	1
515	The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS. Haematologica, 2011, 96, e45-e45.	1.7	1
516	Bringing prognostic scores for chronic myeloid leukemia patients up to date. Expert Review of Hematology, 2011, 4, 373-375.	1.0	1
517	Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges. Cancer Letters, 2012, 325, 18-25.	3.2	1
518	Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies. Leukemia Research, 2012, 36, 682-683.	0.4	1
519	â€œTo switch or not to switch: That is the questionâ€“ More than 10% of ratio @ 3 months: How to treat chronic myeloid leukemia patients with this response?. Leukemia Research, 2013, 37, 995-997.	0.4	1
520	The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?. Leukemia and Lymphoma, 2013, 54, 669-670.	0.6	1
521	Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. Leukemia and Lymphoma, 2014, 55, 204-206.	0.6	1
522	Patient-reported outcomes in acute leukemia: a roadmap for future research. European Journal of Haematology, 2014, 93, 86-87.	1.1	1

#	ARTICLE	IF	CITATIONS
523	Validation of a new proposed relapse risk score (CBC-score) for acute promyelocytic leukaemia. International Journal of Hematology, 2014, 99, 100-101.	0.7	1
524	Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. Clinical Investigation, 2015, 5, 257-265.	0.0	1
525	How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. Expert Opinion on Pharmacotherapy, 2016, 17, 1517-1526.	0.9	1
526	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S313-S314.	0.2	1
527	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 2020, 38, 607-610.	0.8	1
528	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. British Journal of Haematology, 2020, 190, e304-e307.	1.2	1
529	Measuring prognosis in chronic myeloid leukemia: what's new?. Expert Review of Hematology, 2021, 14, 577-585.	1.0	1
530	Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. Expert Review of Hematology, 2021, 14, 645-654.	1.0	1
531	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. BMJ Supportive and Palliative Care, 2020, , bmjspcare-2020-002281.	0.8	1
532	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. Blood, 2018, 132, 2293-2293.	0.6	1
533	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. Blood, 2018, 132, 3006-3006.	0.6	1
534	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. Blood, 2018, 132, 1732-1732.	0.6	1
535	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". Blood, 2020, 136, 35-36.	0.6	1
536	Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. Blood, 2004, 104, 4693-4693.	0.6	1
537	Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). Blood, 2008, 112, 5237-5237.	0.6	1
538	Comorbidities Indexes In Patients Treated with 5-Azacitidine Are a An Useful and Easily Applicable Tool to Refine Prognostic Evaluation. Blood, 2010, 116, 606-606.	0.6	1
539	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	0.6	1
540	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	0.6	1

#	ARTICLE	IF	CITATIONS
541	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of A "Real-life" Patient Population With Chronic Myelogenous Leukemia?. Blood, 2013, 122, 4002-4002.	0.6	1
542	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. Blood, 2015, 126, 4038-4038.	0.6	1
543	Incidence of Severe ($\geq 10g/dl$) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. Blood, 2016, 128, 1903-1903.	0.6	1
544	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. Blood, 2016, 128, 3068-3068.	0.6	1
545	Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. Blood, 2005, 106, 885-885.	0.6	1
546	Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. Blood, 2006, 108, 2667-2667.	0.6	1
547	Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. Blood, 2008, 112, 1949-1949.	0.6	1
548	Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. Blood, 2008, 112, 4281-4281.	0.6	1
549	Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY.. Blood, 2009, 114, 1118-1118.	0.6	1
550	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study.. Blood, 2009, 114, 2763-2763.	0.6	1
551	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.. Blood, 2009, 114, 3302-3302.	0.6	1
552	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. Blood, 2010, 116, 2294-2294.	0.6	1
553	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients.,. Blood, 2011, 118, 3793-3793.	0.6	1
554	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. Blood, 2011, 118, 2751-2751.	0.6	1
555	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. Blood, 2014, 124, 1794-1794.	0.6	1
556	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821.	0.6	1
557	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	0.6	1
558	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). Blood, 2016, 128, 5465-5465.	0.6	1

#	ARTICLE	IF	CITATIONS
559	Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.. Journal of Clinical Oncology, 2018, 36, TPS7081-TPS7081.	0.8	1
560	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4184-4184.	0.6	1
561	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. Blood, 2019, 134, 4179-4179.	0.6	1
562	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	0.6	1
563	Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial. Blood, 2019, 134, 4155-4155.	0.6	1
564	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. Blood, 2021, 138, 3617-3617.	0.6	1
565	Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. Blood, 2021, 138, 4017-4017.	0.6	1
566	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. Blood, 2021, 138, 2581-2581.	0.6	1
567	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. Blood, 2020, 136, 17-18.	0.6	1
568	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	0.6	1
569	Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION. Blood, 2020, 136, 31-32.	0.6	1
570	Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B. Haematologica, 2004, 89, ELT04.	1.7	1
571	Isolated myeloid sarcoma without bone marrow involvement. Clinical Advances in Hematology and Oncology, 2012, 10, 66-7.	0.3	1
572	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. Cell Death and Disease, 2022, 13, .	2.7	1
573	Nilotinib and dasatinib first-line: Are we ready for imatinib replacement?. Leukemia Research, 2011, 35, 1153-1155.	0.4	0
574	Familial occurrence of myelodysplastic syndrome with del(5q). Leukemia and Lymphoma, 2011, 52, 1143-1145.	0.6	0
575	Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?. Leukemia and Lymphoma, 2012, 53, 2073-2074.	0.6	0
576	Are there real benefits of hypomethylating agents for therapy-related myeloid neoplasms?. Leukemia Research, 2013, 37, 485-486.	0.4	0

#	ARTICLE	IF	CITATIONS
577	The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients. <i>Leukemia Research</i> , 2013, 37, 1436-1437.	0.4	0
578	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> . 2013;121(26):5138-5144.. <i>Blood</i> , 2014, 123, 2902-2902.	0.6	0
579	Ponatinib in chronic myeloid leukaemia: ready for first-line?. <i>Lancet Haematology,the</i> , 2015, 2, e352-e353.	2.2	0
580	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015, 90, E95-E96.	2.0	0
581	The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Acta Haematologica</i> , 2015, 134, 57-58.	0.7	0
582	Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes <i>Diabetes</i> , 2015, 7, 493-496.	0.8	0
583	Association between Proteomic Profile and Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S312.	0.2	0
584	Physiciansâ€™ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 204.	1.0	0
585	Special Situations in APL. , 2018, , 203-210.		0
586	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1016-1018.	0.6	0
587	Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S223.	0.2	0
588	Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S289-S290.	0.2	0
589	Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data. <i>Acta Haematologica</i> , 2019, 142, 61-63.	0.7	0
590	First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an â€œoperational cureâ€•. <i>Lancet Haematology,the</i> , 2020, 7, e182-e183.	2.2	0
591	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333.	0.2	0
592	Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 237-238.	1.2	0
593	American Society of Hematology 2020 Podcast Collection: CML. <i>Advances in Therapy</i> , 2021, 38, 26-30.	1.3	0
594	American Society of Hematology 2020 Podcast Collection: MPN. <i>Advances in Therapy</i> , 2021, 38, 16-19.	1.3	0

#	ARTICLE	IF	CITATIONS
595	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
596	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689.	1.3	0
597	CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S326-S327.	0.2	0
598	CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S335-S336.	0.2	0
599	Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S223.	0.2	0
600	Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005, 106, 887-887.	0.6	0
601	Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. <i>Blood</i> , 2006, 108, 3595-3595.	0.6	0
602	Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.. <i>Blood</i> , 2006, 108, 2156-2156.	0.6	0
603	Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 3320-3320.	0.6	0
604	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006, 108, 2158-2158.	0.6	0
605	Improvement of Tolerability and Adverse Events Occurrence during Treatment with Dasatinib Used on a Compassionate Basis in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2007, 110, 4564-4564.	0.6	0
606	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007, 110, 4652-4652.	0.6	0
607	Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 4609-4609.	0.6	0
608	Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. <i>Blood</i> , 2007, 110, 4636-4636.	0.6	0
609	Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy. <i>Blood</i> , 2008, 112, 4288-4288.	0.6	0
610	Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008, 112, 4253-4253.	0.6	0
611	Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008, 112, 5097-5097.	0.6	0
612	Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 3983-3983.	0.6	0

#	ARTICLE	IF	CITATIONS
613	Treatment with Imatinib in Very Elderly (> 75 Years) CML Patients.. Blood, 2008, 112, 1096-1096.	0.6	0
614	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. Blood, 2009, 114, 4160-4160.	0.6	0
615	The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. Blood, 2009, 114, 1124-1124.	0.6	0
616	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. Blood, 2009, 114, 1019-1019.	0.6	0
617	Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. Blood, 2009, 114, 4271-4271.	0.6	0
618	Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. Blood, 2009, 114, 4545-4545.	0.6	0
619	Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. Blood, 2009, 114, 4985-4985.	0.6	0
620	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211.	0.6	0
621	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. Blood, 2009, 114, 1777-1777.	0.6	0
622	Abstract 1805: Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, "deep" and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. , 2010, , .		0
623	Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. Blood, 2010, 116, 4976-4976.	0.6	0
624	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	0.6	0
625	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2220-2220.	0.6	0
626	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia: What Have We Learned Over the Last Twenty Years?.. Blood, 2010, 116, 3423-3423.	0.6	0
627	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279.	0.6	0
628	Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. Blood, 2010, 116, 3077-3077.	0.6	0
629	Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). Blood, 2010, 116, 2927-2927.	0.6	0
630	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	0.6	0

#	ARTICLE	IF	CITATIONS
631	Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study. Blood, 2010, 116, 4953-4953.	0.6	0
632	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. Blood, 2010, 116, 5065-5065.	0.6	0
633	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (>= 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
634	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	0.6	0
635	The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.. Blood, 2010, 116, 3399-3399.	0.6	0
636	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. Blood, 2010, 116, 1229-1229.	0.6	0
637	Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes. Blood, 2011, 118, 2078-2078.	0.6	0
638	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682.	0.6	0
639	Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. Blood, 2011, 118, 1026-1026.	0.6	0
640	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445.	0.6	0
641	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157.	0.6	0
642	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.	0.6	0
643	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	0.6	0
644	Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the â€œGruppo Laziale SMPC Ph Negative â€œ. Blood, 2011, 118, 3854-3854.	0.6	0
645	Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. Blood, 2011, 118, 4866-4866.	0.6	0
646	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.	0.6	0
647	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. Blood, 2012, 120, 4958-4958.	0.6	0
648	Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients. Blood, 2012, 120, 4951-4951.	0.6	0

#	ARTICLE	IF	CITATIONS
649	Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.. Blood, 2012, 120, 2784-2784.	0.6	0
650	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. Blood, 2012, 120, 3163-3163.	0.6	0
651	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. Blood, 2012, 120, 3769-3769.	0.6	0
652	Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy. Blood, 2012, 120, 4234-4234.	0.6	0
653	Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. Blood, 2012, 120, 3742-3742.	0.6	0
654	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	0.6	0
655	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. Blood, 2013, 122, 4000-4000.	0.6	0
656	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. Blood, 2013, 122, 1336-1336.	0.6	0
657	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. Blood, 2013, 122, 2659-2659.	0.6	0
658	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. Blood, 2013, 122, 5229-5229.	0.6	0
659	Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). Blood, 2013, 122, 1594-1594.	0.6	0
660	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. Blood, 2013, 122, 5203-5203.	0.6	0
661	Chronic Myeloid Leukemia. , 2014, , 1-5.		0
662	Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycythemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. Blood, 2014, 124, 1855-1855.	0.6	0
663	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. Blood, 2014, 124, 4532-4532.	0.6	0
664	â€œReal-lifeâ€•Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. Blood, 2014, 124, 5530-5530.	0.6	0
665	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 3687-3687.	0.6	0
666	Systematic Coronary Risk Evaluation (SCORE) Chart Identify Chronic Myeloid Leukemia Patients at Risk of Cardiovascular Diseases during Nilotinib Treatment. Blood, 2014, 124, 4545-4545.	0.6	0

#	ARTICLE	IF	CITATIONS
667	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265.	0.6	0
668	Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1063-1063.	0.6	0
669	Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. <i>Blood</i> , 2014, 124, 5326-5326.	0.6	0
670	Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2014, 124, 3189-3189.	0.6	0
671	Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome. <i>Clinical Management Issues</i> , 2010, 4, 7-11.	0.3	0
672	Nilotinib: selective inhibitor as second-line therapy. <i>Clinical Management Issues</i> , 2010, 4, 3-5.	0.3	0
673	Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib. <i>Clinical Management Issues</i> , 2010, 4, 9-13.	0.3	0
674	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015, 126, 2099-2099.	0.6	0
675	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. <i>Blood</i> , 2015, 126, 1614-1614.	0.6	0
676	Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. <i>Blood</i> , 2015, 126, 1570-1570.	0.6	0
677	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015, 126, 2815-2815.	0.6	0
678	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	0.6	0
679	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. <i>Blood</i> , 2015, 126, 4046-4046.	0.6	0
680	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	0.6	0
681	Chronic Myeloid Leukemia. , 2016, , 1059-1063.		0
682	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016, 128, 3097-3097.	0.6	0
683	Physicians' Attitude Towards Selection of Second Line Therapy with Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2016, 128, 5939-5939.	0.6	0
684	Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1242-1242.	0.6	0

#	ARTICLE	IF	CITATIONS
685	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 5464-5464.	0.6	0
686	Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016, 128, 5473-5473.	0.6	0
687	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016, 128, 5469-5469.	0.6	0
688	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	0.6	0
689	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746.	0.6	0
690	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
691	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518.	0.6	0
692	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741.	0.6	0
693	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516.	0.6	0
694	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
695	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312.	0.6	0
696	Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5471-5471.	0.6	0
697	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	0.6	0
698	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464.	0.6	0
699	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18220-e18220.	0.8	0
700	Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23073-e23073.	0.8	0
701	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
702	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188.	0.6	0

#	ARTICLE	IF	CITATIONS
703	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	0.6	0
704	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153.	0.6	0
705	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487.	0.6	0
706	Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1486-1486.	0.6	0
707	Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy. <i>Blood</i> , 2021, 138, 1943-1943.	0.6	0
708	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
709	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
710	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
711	First Line Treatment with Hydroxyurea in Patients with Polycitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
712	Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments. <i>Advances in Therapy</i> , 2022, 39, 1101.	1.3	0
713	Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia. <i>Haematologica</i> , 2004, 89, ECR20.	1.7	0
714	Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 266-8.	0.3	0
715	Acute promyelocytic leukemia: pathophysiology and clinical results update. , 0, , 131-140.		0
716	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". <i>Journal of Clinical Medicine</i> , 2022, 11, 2596.	1.0	0
717	Future Management Of Chronic Myeloid Leukemia: From Dose Optimization To New Agents. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
718	Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group. <i>Leukemia and Lymphoma</i> , 2022, 63, 2751-2753.	0.6	0